• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Coagulation patterns in bovine left heart bypass with phospholipid versus heparin surface coating.

作者信息

von Segesser L K, Olah A, Leskosek B, Turina M

机构信息

Clinic for Cardiovascular Surgery, University Hospital, Zürich, Switzerland.

出版信息

ASAIO J. 1993 Jan-Mar;39(1):43-6.

PMID:8439679
Abstract

The current study was designed to evaluate tubing sets with either polymeric phospholipids or ionically bound heparin in six bovine experiments (body weight, 70 +/- 5 kg). No heparin was given systemically. Left heart bypass was started with 300 ml of clear priming solution and maintained over 6 hours (50 ml/kg/min). Coagulation studies included platelet counts, activated coagulation time (ACT), thrombin time (TT), fibrinogen (Factor I), antithrombin III (AT III), and fibrinopeptide A (FPA). Normalized platelet levels dropped from 100 +/- 12% before to 86 +/- 13% after 6 hours of left heart bypass for heparin, compared with 100 +/- 46% to 90 +/- 44% for phospholipid coating (NS). The ACT increased from 146 +/- 7 sec at 10 min to 159 +/- 16 sec after 6 hours for heparin, compared with 122 +/- 4 to 126 +/- 5 sec for phospholipid (p < 0.05). Thrombin time changed from 18 +/- 0 sec before to 19 +/- 1 sec after 6 hours for heparin, as compared with 16 +/- 1 sec to 18 +/- 1 sec for phospholipid (NS). Factor I levels decreased from 1.5 +/- 0.3 g/L to 1.3 +/- 0.1 g/L for heparin, compared with 1.5 +/- 0.2 g/L to 1.4 +/- 0.3 g/L for phospholipid. Antithrombin III levels changed from 102 +/- 26% to 91 +/- 7% for heparin, compared with 123 +/- 12% to 118 +/- 12% for phospholipid. Fibrinopeptide A levels changed from 100 +/- 60% to 130 +/- 13% for heparin, compared with 100 +/- 11% to 99 +/- 6% for phospholipid (P < 0.05). No macroscopic red clots were found in either group.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Coagulation patterns in bovine left heart bypass with phospholipid versus heparin surface coating.
ASAIO J. 1993 Jan-Mar;39(1):43-6.
2
[Thrombosis-resistant heparin-coated diffusion membrane oxygenators: an experimental study].
Swiss Surg Suppl. 1996;Suppl 1:36-40.
3
Increased activation of the coagulation and fibrinolytic systems leads to hemorrhagic complications during left ventricular assist implantation.凝血和纤溶系统的激活增加会导致左心室辅助装置植入期间出现出血并发症。
Circulation. 1996 Nov 1;94(9 Suppl):II227-34.
4
Heparin surface coated hard shell venous reservoirs: experimental evaluation ex vivo.
Int J Artif Organs. 1994 Dec;17(12):651-6.
5
Blood coagulability and hematological changes in calves with chronic centrifugal biventricular bypass pumps.
J Surg Res. 1994 Jan;56(1):13-9. doi: 10.1006/jsre.1994.1003.
6
Coagulation patterns during deheparinization with immobilized polycation.
ASAIO J. 1994 Jul-Sep;40(3):M565-9. doi: 10.1097/00002480-199407000-00062.
7
[Changes in platelets and blood coagulation during prolonged ECLA with a heparin bonded hollow fiber membrane lung].
Masui. 1990 Jul;39(7):845-53.
8
Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis.
Clin Nephrol. 1981 May;15(5):252-8.
9
Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.术前接受依诺肝素治疗的冠状动脉手术患者的肝素抵抗和血小板活化增加。
Eur J Cardiothorac Surg. 2006 Jun;29(6):933-40. doi: 10.1016/j.ejcts.2006.02.007. Epub 2006 May 3.
10
Flow rate dependent ex vivo deheparinization with immobilized cationic ligand.固定化阳离子配体介导的流速依赖性体外脱肝素化
ASAIO J. 1997 Sep-Oct;43(5):M487-9.

引用本文的文献

1
Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries.磷酰胆碱涂层支架在正常猪冠状动脉中的生物相容性
Heart. 2000 Mar;83(3):338-45. doi: 10.1136/heart.83.3.338.